ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

ClinicalTrials.gov ID: NCT02048722

Public ClinicalTrials.gov record NCT02048722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Study identification

NCT ID
NCT02048722
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Northwestern University
Other
Enrollment
31 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 12, 2014
Primary completion
Oct 13, 2019
Completion
Oct 11, 2021
Last update posted
Apr 24, 2022

2014 – 2021

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Sarcoma Oncology Center Santa Monica California 90403
Mayo Clinic in Florida Jacksonville Florida 32224-9980
Northwestern University Chicago Illinois 60611
University of Iowa Iowa City Iowa 52246
University of Minnesota Medical Center-Fairview Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Washington University-St. Louis St Louis Missouri 63110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02048722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 24, 2022 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02048722 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →